Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

BSH/ISH 2016 | The future of CML treatment and cures

Giuseppe Saglio • 18 Apr 2016

BSH/ISH 2016

Chronic Myeloid Leukemia Imatinib

DASISION

Giuseppe Saglio, MD of the University of Turin, Turin, Italy discusses the future of chronic myeloid leukemia (CML) treatment. According to Prof Saglio, for a specific group of patients, the future will be a real cure. This may only be achievable in 10-15% of patients even with imatinib treatment. With 2nd generation tyrosine kinase inhibitors (TKI), this may be improved to 30-35%.. There are, however, patients that cannot receive TKI treatment. Prof Saglio discusses the need to find the best combination therapy, which may be beneficial for all patients.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.

An insight into the aims of the Eurasian Hematology-Oncology Group

Giuseppe Saglio • 25 Oct 2022

The current standard of care in CML and insights into the use of first- and second-generation TKIs

Giuseppe Saglio • 25 Oct 2022

Addressing the issue of resistance to TKIs in CML

Giuseppe Saglio • 28 Oct 2022

TKI-related toxicities in CML & the importance of long-term monitoring

Giuseppe Saglio • 28 Sep 2022

Related Videos

Do all patients require maintenance therapy following alloSCT?

Mark Levis • 16 Apr 2024

Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients

Caspian Oliai • 10 Dec 2023

A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies

Tapan Kadia • 14 Dec 2023

An overview of trials investigating asciminib in the treatment of Ph+ CML

Michael Mauro • 18 Dec 2023